Reasons to believe: The potential of imaging in CNS drug development

Imaging in CNS Drug Discovery and Development: Implications for Disease and Therapy

Volumn , Issue , 2009, Pages 381-386

  Hargreaves, Richard ^a   Bullmore, Edward ^b   Becerra, Lino R ^c   Borsook, David ^c  

^a MERCK RESEARCH LABORATORIES   (United States)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c MCLEAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84900677542     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4419-0134-7_23     Document Type: Chapter

References (21)

1. Borsook D, Becerra L, Hargreaves R (2006) A role for fMRI in optimizing CNS drug development. Nat Rev Drug Discov 5(5):411-424
2. Rudin M, Mueggler T, Allegrini PR, Baumann D, Rausch M (2003) Characterization of CNS disorders and evaluation of therapy using structural and functional MRI. Anal Bioanal Chem 377(6):973-981
3. Beckmann N, Laurent D, Tigani B, Panizzutti R, Rudin M (2004) Magnetic resonance imaging in drug discovery: lessons from disease areas. Drug Discov Today 9(1):35-42
4. Wise RG, Tracey I (2006) The role of fMRI in drug discovery. J Magn Reson Imaging 23(6):862-876
5. Matthews PM, Honey GD, Bullmore ET (2006) Applications of fMRI in translational medicine and clinical practice. Nat Rev Neurosci 7(9):732-744
6. Pohlmann A, Barjat H, Tilling LC, James MF (2007) Pharmacological fMRI - challenges in analysing drug-induced single-event BOLD responses. Conf Proc IEEE Eng Med Biol Soc. 2007:3411-3416
7. Borsook D, Bleakman D, Hargreaves R, Upadhyay J, Schmidt KF, Becerra L (2008) A "BOLD" experiment in defining the utility of fMRI in drug development. Neuroimage 42(2):461-466
8. Prichard JW, Alger JR, Turner R (1999) Brain imaging: the NMR revolution. Interview by Clare Thompson. BMJ 319(7220):1302
9. Gur RE (2002) Functional imaging is fulfilling some promises. Am J Psychiatry 159(5):693-694
10. Logothetis NK (2002) The neural basis of the blood-oxygen-level-dependent functional magnetic resonance imaging signal. Philos Trans R Soc Lond B Biol Sci 357(1424):1003-1037
11. Logothetis NK (2008) What we can do and what we cannot do with fMRI. Nature 453(7197):869-878
12. Hyder F, Kida I, Behar KL, Kennan RP, Maciejewski PK, Rothman DL (2001) Quantitative functional imaging of the brain: Towards mapping neuronal activity by BOLD fMRI. NMR Biomed 14(7-8):413-431
13. Beckmann CF, DeLuca M, Devlin JT, Smith SM (2005) Investigations into resting-state connectivity using independent component analysis. Philos Trans R Soc Lond B Biol Sci 360(1457):1001-1013
14. Mori S, Zhang J (2006) Principles of diffusion tensor imaging and its applications to basic neuroscience research. Neuron 51(5):527-539
15. Jissendi Tchofo P, Baleriaux D (2009) Brain (1) H-MR spectroscopy in clinical neuroimaging at 3T. J Neuroradiol 36:24-40
16. Uppoor RS, Mummaneni P, Cooper E, Pien HH, Sorensen AG, Collins J et al (2008) The use of imaging in the early development of neuropharmacological drugs: a survey of approved NDAs. Clin Pharmacol Ther 84(1):69-74
17. Wong DF, Tauscher J, Grunder G (2009) The role of imaging in proof of concept for CNS drug discovery and development. Neuropsychopharmacology 34(1):187-203
18. Jack CR Jr, Slomkowski M, Gracon S, Hoover TM, Felmlee JP, Stewart K et al (2003) MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD. Neurology 60(2):253-260
19. Jack CR Jr, Bernstein MA, Fox NC, Thompson P, Alexander G, Harvey D et al (2008) The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging 27(4):685-691
20. Cummings JL (2008) Optimizing phase II of drug development for disease-modifying compounds. Alzheimers Dement 4(1 Suppl 1):S15-S20
21. Bickle M (2008) High-content screening: a new primary screening tool? IDrugs 11(11):822-826